The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

A man in his mid-60s with a history of diabetes, hypertension, gastroesophageal reflux disease (GERD), and lung cancer is transported from home to the emergency department (ED) after he ...

Mendelian randomization analysis of genome-wide association study data suggests schizophrenia and major depressive disorder may cause constipation. Constipation, a common and often debilitating ...

Compared with White children, Black and Hispanic children also received less testing, including brain MRI. HealthDay News — Compared with non-Hispanic White (NHW) children, non-Hispanic Black ...

Leukocyte count linked to severity of post-acute sequelae of SARS-CoV-2 infection, but not of PASC occurrence or related cognitive outcomes ...

The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to ...

Secretary of State Marco Rubio announced the waiver on Tuesday; however, exactly what it covers remains unclear. While the waiver does allow for the resumption of distributing HIV medications, the ...

Patients treated with platinum-based agents and taxanes had the highest prevalence of chronic painful CIPN (40.44% and 38.35%, respectively). HealthDay News — The pooled prevalence of chronic ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

Women aged 18 to 45 years with IBD were invited to complete a survey regarding knowledge, attitude, and beliefs about contraception.

A retrospective analysis showed IV edaravone in participants with ALS was associated with fewer reported disease progression milestones and deaths than control.